A Phase I/II Study of De-immunized DI-Leu16-IL2 Immunocytokine Administered Subcutaneously in Patients with B-cell Non-Hodgkin Lymphoma (NHL)
An open-label, dose-escalation trial of the safety, tolerability, pharmacokinetics (PK),
biological, and clinical activity of DI-Leu16-IL2 administered to patients with CD20
(B-lymphocyte antigen CD20) positive Non-Hodgkin Lymphoma (NHL) that have failed standard
rituximab-containing therapy. Following peripheral blood B cell depletion with rituximab (if
needed) each patient will receive DI-Leu16-IL2 administered as a subcutaneous (SC) injection
for three consecutive days every three weeks.
View more details from ClinicalTrials.gov.
For more information about a clinical trial, clinical trial eligibility, or informed consent, contact our research nurses by phone or email:
Please Note: Any eligibility criteria noted are subject to change. Our research nurses can provide you with the most current eligibility and exclusion criteria. Any study involvement to be undertaken must ultimately be determined on an individual basis.